PI
MYGN icon

PEAK6 Investments’s Myriad Genetics MYGN Stock Holding History

PEAK6 Investments’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,700
Closed -$147K – 4941
2022
Q3 		$147K Sell
7,700
-100
-1% -$2.29K ﹤0.01% 3857
2022
Q2 		$142K Buy
7,800
+7,700
+7,700% +$160K ﹤0.01% 5025
2022
Q1 		$3K Buy
+100
New +$2.56K ﹤0.01% 4943
2019
Q2 		– Sell
-92,700
Closed -$3.08M – 4085
2019
Q1 		$3.08M Sell
92,700
-600
-0.6% -$18.3K 0.02% 1009
2018
Q4 		$2.71M Buy
93,300
+34,200
+58% +$1.23M 0.02% 1017
2018
Q3 		$2.72M Buy
+59,100
New +$2.63M 0.01% 1207

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

PEAK6 Investments's MYGN Position: Q2 2023 in Review

PEAK6 Investments sold out of Myriad Genetics (MYGN) in Q2 2023, closing a stake of 9,900 shares — an estimated $230K sold.

PEAK6 Investments first reported a position in MYGN in Q3 2018 and held it in 4 quarters. The position peaked at $466K in Q4 2018. 188 funds tracked by Wall St. Rank hold MYGN as of Q2 2023.

  • PEAK6 Investments reported no remaining Myriad Genetics position as of Q2 2023 after selling out during the quarter.
  • PEAK6 Investments sold 9,900 Myriad Genetics shares in Q2 2023, an estimated $230K.
  • PEAK6 Investments first reported a position in Myriad Genetics in Q3 2018 and held it in 4 quarters.
  • PEAK6 Investments's Myriad Genetics position peaked at $466K in Q4 2018.
  • 188 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2023.

Based on PEAK6 Investments's 13F filing for Q2 2023, filed 11 Aug 2023.